TV Spot on EpiPen Pulled After FDA Warning Letter

Devices & Diagnostics Letter
A A
Pfizer agreed to pull a 60-second direct-to-consumer (DTC) TV ad promoting a pair of drug-device combination products to treat severe allergic reactions after the FDA flagged it for overstating the products’ efficacy.

To View This Article:

Login

Subscribe To Devices & Diagnostics Letter

Buy This Article Now

Add this article to your cart for $25.00